Literature DB >> 27291644

Selective mediastinal node irradiation in non-small cell lung cancer in the IMRT/VMAT era: How to use E(B)US-NA information in addition to PET-CT for delineation?

Stephanie T Peeters1, Christophe Dooms2, Angela Van Baardwijk3, Anne-Marie C Dingemans4, Hanneke Martinussen4, Johan Vansteenkiste2, Herbert Decaluwé5, Paul De Leyn5, Jonas Yserbyt2, Kristiaan Nackaerts2, Walter De Wever6, Christophe M Deroose7, Dirk De Ruysscher8.   

Abstract

BACKGROUND: FDG-PET-CT-based selective lymph node (LN) irradiation is standard using 3D-conformal techniques for locally advanced NSCLC. With newer techniques (intensity-modulated/volumetric-arc therapy (IMRT/VMAT)), the dose to non-involved adjacent LN decreases, which raises the question whether FDG-PET-CT-delineation is still safe. We therefore evaluated the impact of adding linear endosonography with needle aspiration (E(B)US-NA) to FDG-PET-CT in selective nodal irradiation.
METHODS: Based on literature data on sensitivity and specificity of E(B)US-NA in FDG-PET-CT-staged NSCLC, false negative (FN) rates for different constellations of CT, PET and E(B)US-NA were calculated. The algorithm was tested on consecutive patients with N2/N3 disease referred for radiotherapy in Leuven and Maastricht.
RESULTS: An algorithm determining when to include LN in the GTV is proposed, based on data from 5 meta-analyses. Adding E(B)US-NA to FDG-PET-CT decreases the FN-rate, but for PET-positive and E(B)US-negative LN, FN rates are still 14-16%. In Leuven 520 LN were analyzed, in Maastricht 364 LN; with E(B)US-NA a geographical miss was avoided in 2 (2/40=5%) and 1 (1/28=4%) patients, respectively.
CONCLUSIONS: E(B)US-NA in addition to FDG-PET-CT for mediastinal staging decreases the risk of a geographical miss with 4-5%. The impact of this small decrease on survival is unknown. The proposed algorithm may guide the radiation oncologist when to include LN in the nodal GTV.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Endobronchial ultrasound (EBUS); Intensity-modulated radiotherapy (IMRT); Non-small cell lung cancer (NSCLC); PET–CT based delineation; Radiotherapy; Volumetric arc therapy (VMAT)

Mesh:

Substances:

Year:  2016        PMID: 27291644     DOI: 10.1016/j.radonc.2016.05.023

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  12 in total

Review 1.  Challenges in the target volume definition of lung cancer radiotherapy.

Authors:  Susan Mercieca; José S A Belderbos; Marcel van Herk
Journal:  Transl Lung Cancer Res       Date:  2021-04

2.  Impact of EBUS-TBNA in addition to [18F]FDG-PET/CT imaging on target volume definition for radiochemotherapy in stage III NSCLC.

Authors:  Maja Guberina; Kaid Darwiche; Hubertus Hautzel; Till Ploenes; Christoph Pöttgen; Nika Guberina; Ken Herrmann; Lale Umutlu; Axel Wetter; Dirk Theegarten; Clemens Aigner; Wilfried Ernst Erich Eberhardt; Martin Schuler; Rüdiger Karpf-Wissel; Martin Stuschke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-05       Impact factor: 9.236

3.  18F-fluorodeoxyglucose positron-emission tomography (FDG-PET)-Radiomics of metastatic lymph nodes and primary tumor in non-small cell lung cancer (NSCLC) - A prospective externally validated study.

Authors:  Sara Carvalho; Ralph T H Leijenaar; Esther G C Troost; Janna E van Timmeren; Cary Oberije; Wouter van Elmpt; Lioe-Fee de Geus-Oei; Johan Bussink; Philippe Lambin
Journal:  PLoS One       Date:  2018-03-01       Impact factor: 3.240

4.  Added value of invasive needle techniques in mediastinal and hilar nodal staging of clinical N0-N1 non-small cell lung cancer after positron emission tomography.

Authors:  Marie-May Collin-Castonguay; Julien Guinde; Laurie Laflamme; Sabrina Marcoux; Marc Fortin
Journal:  Clin Transl Radiat Oncol       Date:  2020-06-18

5.  Systematic endobronchial ultrasound-guided transbronchial needle aspiration improves radiotherapy planning in non-small cell lung cancer.

Authors:  Aidan Joseph Cole; Nicholas Hardcastle; Guy-Anne Turgeon; Roshini Thomas; Louis B Irving; Barton R Jennings; David Ball; Tomas Kron; Daniel P Steinfort; Shankar Siva
Journal:  ERJ Open Res       Date:  2019-07-15

Review 6.  Practical implications to contemplate when considering radical therapy for stage III non-small-cell lung cancer.

Authors:  Claire L Storey; Gerard G Hanna; Alastair Greystoke
Journal:  Br J Cancer       Date:  2020-12       Impact factor: 7.640

Review 7.  Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0.

Authors:  Sofia C Vaz; Judit A Adam; Roberto C Delgado Bolton; Pierre Vera; Wouter van Elmpt; Ken Herrmann; Rodney J Hicks; Yolande Lievens; Andrea Santos; Heiko Schöder; Bernard Dubray; Dimitris Visvikis; Esther G C Troost; Lioe-Fee de Geus-Oei
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-01-13       Impact factor: 10.057

Review 8.  Safe performance of diagnostic bronchoscopy/EBUS during the SARS-CoV-2 pandemic.

Authors:  Daniel P Steinfort; Felix J F Herth; Louis B Irving; Phan T Nguyen
Journal:  Respirology       Date:  2020-05-13       Impact factor: 6.175

9.  Comparison of Involved Field Radiotherapy versus Elective Nodal Irradiation in Stage IIIB/C Non-Small-Cell Lung Carcinoma Patients Treated with Concurrent Chemoradiotherapy: A Propensity Score Matching Study.

Authors:  Erkan Topkan; Yurday Ozdemir; Ozan Cem Guler; Ahmet Kucuk; Ali Ayberk Besen; Huseyin Mertsoylu; Duygu Sezen; Eyub Yasar Akdemir; Ahmet Sezer; Yasemin Bolukbasi; Berrin Pehlivan; Ugur Selek
Journal:  J Oncol       Date:  2020-09-04       Impact factor: 4.375

Review 10.  Video-assisted mediastinoscopic lymphadenectomy (VAMLA) for staging & treatment of non-small cell lung cancer (NSCLC).

Authors:  Marc Hartert; Jan Tripsky; Martin Huertgen
Journal:  Mediastinum       Date:  2020-03-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.